ETF Holdings Breakdown of SMMT

Stock NameSummit Therapeutics PLC
TickerSMMT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS86627T1088

News associated with SMMT

Summit Therapeutics (NASDAQ:SMMT) Stock Rating Lowered by StockNews.com
StockNews.com lowered shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) from a hold rating to a sell rating in a research note published on Monday morning. A number of other analysts have also recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Summit Therapeutics in a report on Wednesday, April […] - 2025-05-06 05:36:50
SMMT Crosses Above Average Analyst Target
In recent trading, shares of Summit Therapeutics Inc (Symbol: SMMT) have crossed above the average analyst 12-month target price of $35.57, changing hands for $36.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade - 2025-04-25 11:00:49
JPMorgan Chase & Co. Sells 23,068 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)
JPMorgan Chase & Co. trimmed its position in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 14.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 139,581 shares of the company’s stock after selling 23,068 shares during the period. JPMorgan Chase & Co.’s holdings in Summit Therapeutics were worth $2,491,000 at the end of […] - 2025-04-24 07:24:52
Bank of Montreal Can Reduces Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)
Bank of Montreal Can lessened its position in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 13.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 84,225 shares of the company’s stock after selling 13,350 shares during the period. Bank of Montreal Can’s holdings in Summit Therapeutics were worth $1,503,000 at the end of […] - 2025-04-18 08:06:58
National Bank of Canada FI Acquires New Shares in Summit Therapeutics Inc. (NASDAQ:SMMT)
National Bank of Canada FI bought a new position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm bought 1,664 shares of the company’s stock, valued at approximately $30,000. Several other large investors also recently bought and sold shares of SMMT. XTX Topco Ltd raised its […] - 2025-04-13 08:44:55
Orion Portfolio Solutions LLC Makes New $193,000 Investment in Summit Therapeutics Inc. (NASDAQ:SMMT)
Orion Portfolio Solutions LLC acquired a new stake in shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 10,829 shares of the company’s stock, valued at approximately $193,000. Other institutional investors have also recently made […] - 2025-04-11 09:06:59
Summit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by Citigroup
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was upgraded by equities research analysts at Citigroup from a “neutral” rating to a “buy” rating in a report issued on Wednesday, MarketBeat.com reports. The firm currently has a $35.00 target price on the stock, up from their prior target price of $23.00. Citigroup’s target price would indicate […] - 2025-03-28 06:02:49
Summit Therapeutics (NASDAQ:SMMT) Research Coverage Started at Cantor Fitzgerald
Cantor Fitzgerald began coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) in a research report sent to investors on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating on the stock. A number of other brokerages have also commented on SMMT. HC Wainwright reissued a “buy” rating and set a $44.00 price […] - 2025-03-24 06:34:45
Bank of New York Mellon Corp Has $5.95 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT)
Bank of New York Mellon Corp increased its position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 33.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 333,510 shares of the company’s stock after purchasing an additional 84,117 shares during […] - 2025-03-17 07:15:01
11,277 Shares in Summit Therapeutics Inc. (NASDAQ:SMMT) Bought by New York Life Investment Management LLC
New York Life Investment Management LLC bought a new position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 11,277 shares of the company’s stock, valued at approximately $201,000. A number of other large […] - 2025-03-06 10:59:02
New York State Common Retirement Fund Acquires 4,600 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)
New York State Common Retirement Fund increased its stake in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 18.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 29,377 shares of the company’s stock after acquiring an additional 4,600 shares during the period. New York State Common Retirement Fund’s holdings in Summit Therapeutics […] - 2025-03-05 10:18:54
Summit Therapeutics Inc. (NASDAQ:SMMT) Shares Bought by Principal Financial Group Inc.
Principal Financial Group Inc. boosted its stake in shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 252.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 205,150 shares of the company’s stock after purchasing an additional 147,003 shares during the period. Principal Financial Group Inc.’s holdings in Summit Therapeutics were worth $3,661,000 at […] - 2025-03-05 09:04:58
Rhumbline Advisers Boosts Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)
Rhumbline Advisers raised its holdings in shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 4.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 125,202 shares of the company’s stock after acquiring an additional 5,394 shares during the quarter. Rhumbline Advisers’ holdings […] - 2025-03-04 08:12:49
Summit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC Wainwright
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $44.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 140.44% from the company’s current price. […] - 2025-02-27 08:44:56
Summit Therapeutics (NASDAQ:SMMT) Stock Rating Lowered by StockNews.com
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Tuesday. Other research analysts also recently issued research reports about the stock. Wells Fargo & Company began coverage on shares of Summit Therapeutics in a research note on Wednesday, […] - 2025-02-27 06:46:43
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $33.57 Average Price Target from Analysts
Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average […] - 2025-02-27 06:09:05
CIBC Asset Management Inc Has $385,000 Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)
CIBC Asset Management Inc lifted its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 5.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 21,577 shares of the company’s stock after purchasing an additional 1,132 shares during the period. CIBC Asset Management Inc’s holdings in Summit Therapeutics were worth $385,000 as of its […] - 2025-02-24 09:33:18
abrdn plc Boosts Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)
abrdn plc lifted its stake in shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 13.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,290,425 shares of the company’s stock after acquiring an additional 154,139 shares during the […] - 2025-02-07 09:29:00
SG Americas Securities LLC Sells 19,587 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)
SG Americas Securities LLC lessened its stake in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 59.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 13,169 shares of the company’s stock after selling 19,587 shares during the period. SG Americas Securities LLC’s holdings in Summit Therapeutics were worth $235,000 at the end of […] - 2025-02-07 08:25:46

SMMT institutional holdings

The following institutional investment holdings of SMMT have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 351,143USD 8,655,675
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 351,143USD 8,655,675 1.5%
Total =702,286 USD 17,311,350
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.